Investor Presentation - Financial and operational Review for the quarter and year ended March 31,2026.
PRIVISCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Privi Speciality Chemicals reported strong FY26 results with total income of Rs.2,583 crore, up 22% YoY, crossing the Rs.2,500 crore milestone. EBITDA surged 40% to Rs.665 crore with margins expanding 342 bps to 25.8%. PAT jumped 75% to Rs.328 crore. The company generated Rs.550 crore operating cash flow and reduced total debt by Rs.113 crore despite Rs.320 crore CAPEX investment. Q4 standalone revenue was Rs.726 crore with 25.4% EBITDA margin. The company reaffirmed its 5K:1K vision targeting Rs.5,000 crore revenue and Rs.1,000 crore+ EBITDA by FY29-30, with margins expected to sustain above 20% through operational efficiency and improved product mix. PRIGIV JV with Givaudan achieved positive PAT in Q4 FY26.
The strong margin expansion and debt reduction indicate improving operational efficiency and financial health, which should be positive for the stock. The reaffirmed medium-term targets and clear path to 2x revenue growth provide visibility on future earnings potential.